Noboru Nakaigawa

Novel mutations of the MET proto-oncogene in papillary renal carcinomas

Laura S. Schmidt, Kerstin Junker, Noboru Nakaigawa et al. · Oncogene · 1999 · 505 citations

Medicine, Molecular Genetics, Oncology +13

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Activating mutations for the Met tyrosine kinase receptor in human cancer

Michael Jeffers, Laura S. Schmidt, Noboru Nakaigawa et al. · Proceedings of the National Academy of Sciences · 1997 · 440 citations

Medicine, Molecular Biology, Oncology +17

Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development

Hitoshi Ishiguro, Noboru Nakaigawa, Yasuhide Miyoshi et al. · The Prostate · 2005 · 213 citations · Full text

Medicine, Molecular Biology, Oncology +16

Comprehensive mutational analysis of the <i>VHL</i> gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters

Keiichi Kondo, Masahiro Yao, Minoru Yoshida et al. · Genes Chromosomes and Cancer · 2002 · 194 citations

Medicine, Genetics, Oncology +15